Global Search

Hide Filters

Showing 2041 results

Press release / Jan 09, 2026

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT…
Press release / Aug 21, 2017

Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistant

Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la…
Press release / Oct 25, 2016

Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster

Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +…
Press release / Oct 31, 2017

Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy

Submission based on updated analyses from global, multi-center Phase II JULIET study, which met primary endpoint, including 6-month data to be presented at ASH 2017 Kymriah has demonstrated…
Press release / Sep 22, 2018

Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be…
Press release / Sep 22, 2018

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period …
Press release / May 31, 2017

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…
Press release / Jul 30, 2018

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
Press release / Jul 18, 2019

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +…
Press release / Mar 30, 2021

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that…

‹ Previous page
1
…
75
76
77
78
79
80
81
…
205
› Next page